Evidence map›Paper›PMID 29253863›Full record

ArticlePLoS pathogens2017

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.

Radhika Gopal, Kelli Jackson, Netanel Tzarum, Leopold Kong, Andrew Ettenger, Johnathan Guest, Jennifer M Pfaff, Trevor Barnes, Andrew Honda, Erick Giang and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Radhika GopalDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States of America.
Kelli JacksonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States of America.ORCID 0000-0002-8760-8216
Netanel TzarumDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States of America.
Leopold KongDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States of America.
Andrew EttengerIntegral Molecular, Inc., Philadelphia, PA, United States of America.ORCID 0000-0003-2258-4329
Johnathan GuestIntegral Molecular, Inc., Philadelphia, PA, United States of America.
Jennifer M PfaffIntegral Molecular, Inc., Philadelphia, PA, United States of America.
Trevor BarnesIntegral Molecular, Inc., Philadelphia, PA, United States of America.
Andrew HondaDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States of America.
Erick GiangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States of America.
Edgar DavidsonIntegral Molecular, Inc., Philadelphia, PA, United States of America.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States of America.ORCID 0000-0002-6469-2419
Benjamin J DoranzIntegral Molecular, Inc., Philadelphia, PA, United States of America.
Mansun LawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, United States of America.ORCID 0000-0002-8934-9756
Scripps Research Institute · USIntegral Molecular (United States) · US

Funding

Structure Determination Core at SSRLU54GM094586 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI WUTHRICH, KURT · 2010 to 2014
$40.1M
Understanding human neutralizing antibodies to hepatitis C virusR01AI079031 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2008 to 2017
$4.6M
Novel HCV vaccine antigens targeting conserved neutralizing epitopesU19AI123861 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2016 to 2020
$4.6M
Structure and function of Hepacivirus envelope glycoproteinR01AI123365 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN, WILSON, IAN A · 2016 to 2020
$3.1M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007606 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1999 to 2013
$2.1M
Dissecting virus neutralizing determinants to guide HCV vaccine developmentR01AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2014 to 2017
$1.5M
Dissecting virus neutralizing determinants to guide HCV vaccine developmentR56AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2013 to 2013
$793k
NIAID NIH HHS HHSN272201400028CNIAID NIH HHS HHSN272201400058CNIAID NIH HHS R01 AI079031NIAID NIH HHS R01 AI106005NIAID NIH HHS R01 AI123365NIAID NIH HHS R56 AI106005NIAID NIH HHS T32 AI007606NIAID NIH HHS U19 AI123861NIGMS NIH HHS U54 GM094586
6 · The paper itself

Abstract

The hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a non-covalently linked heterodimer on the viral surface that mediates viral entry. E1, E2 and the heterodimer complex E1E2 are candidate vaccine antigens, but are technically challenging to study because of difficulties in producing natively folded proteins by standard protein expression and purification methods. To better comprehend the antigenicity of these proteins, a library of alanine scanning mutants comprising the entirety of E1E2 (555 residues) was created for evaluating the role of each residue in the glycoproteins. The mutant library was probed, by a high-throughput flow cytometry-based assay, for binding with the co-receptor CD81, and a panel of 13 human and mouse monoclonal antibodies (mAbs) that target continuous and discontinuous epitopes of E1, E2, and the E1E2 complex. Together with the recently determined crystal structure of E2 core domain (E2c), we found that several residues in the E2 back layer region indirectly impact binding of CD81 and mAbs that target the conserved neutralizing face of E2. These findings highlight an unexpected role for the E2 back layer in interacting with the E2 front layer for its biological function. We also identified regions of E1 and E2 that likely located at or near the interface of the E1E2 complex, and determined that the E2 back layer also plays an important role in E1E2 complex formation. The conformation-dependent reactivity of CD81 and the antibody panel to the E1E2 mutant library provides a global view of the influence of each amino acid (aa) on E1E2 expression and folding. This information is valuable for guiding protein engineering efforts to enhance the antigenic properties and stability of E1E2 for vaccine antigen development and structural studies.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, ViralAntigens, ViralEpitope MappingEpitopesHepacivirusHigh-Throughput Screening AssaysHumansModels, MolecularMutagenesisProtein EngineeringProtein FoldingProtein StabilityRecombinant ProteinsAntibodies, MonoclonalAntibodies, ViralAntigens, ViralCD81 protein, humanE1 protein, Hepatitis C virusEpitopesglycoprotein E2, Hepatitis C virusRecombinant ProteinsTetraspanin 28Viral Envelope ProteinsViral Hepatitis Vaccines

Identifiers

PMID29253863
PMCPMC5749897
OpenAlexW2780150340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.